Ton Schumacher Group
Molecular Oncology & Immunology
There is now abundant clinical evidence that the T cell-based immune system can control the growth of human cancers. My ambition is three-fold: 1). To develop novel technologies that can be utilized to understand how T cells recognize and destroy human cancers; 2). To exploit these technologies to reveal the mode of action of clinically used immunotherapies; 3). To use the resulting knowledge to design more specific and more effective immune interventions. Over the past years, a major focus of our work has been to understand which tumor antigens play a central role in the clinical activity of present-day cancer immunotherapeutics. With this knowledge reaching the stage where biotech development forms the logical next step, our subsequent goal is to help crack the code that determines the specificity of TCRs reactive against tumor antigens and other antigens.